As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Scientists in China have found a new potential drug target for weight loss. Blocking a protein called CD44 has been shown to ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively, in Phase Ib single ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

Semaglutide may help reduce alcohol cravings and intake, according to a clinical trial. Participants receiving the drug drank ...

It is now critical to understand HIMS' legal pathway to selling personalized doses since it has to be the primary mechanism to sell semaglutide going forward," the Leerink Partners analysts wrote.

This came after Alkem Laboratories presented BE study protocol vide no. BIOS/2024/128, Version No. 01, Dated 17.07.2024 and ...